Dr Wade R Smith, MD | |
701 E Hampden Ave, #515, Englewood, CO 80113-2736 | |
(303) 209-2503 | |
(303) 761-0803 |
Full Name | Dr Wade R Smith |
---|---|
Gender | Male |
Speciality | Orthopedic Surgery |
Experience | 34 Years |
Location | 701 E Hampden Ave, Englewood, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1790888691 | NPI | - | NPPES |
10025942600 | Medicaid | NE | |
1790888691 | Medicaid | WY | |
18455573 | Medicaid | CO |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207X00000X | Orthopaedic Surgery | MD048555L (Pennsylvania) | Secondary |
207X00000X | Orthopaedic Surgery | 36792 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Hca-healthone Dba Swedish Medical Center | Englewood, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Healthone Clinic Services - Orthopedic Specialists Llc | 5799972725 | 51 |
News Archive
The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
The first mobile safety laboratory to operate under Biosafety Level 3 has been in use in South Africa since May 2011. As development of the Fraunhofer Institute for Biomedical Engineering in St. Ingbert, this special truck is used for testing and advising patients with AIDS and tuberculosis. The mobile laboratory can save patients' lives in remote areas because it cuts the waiting time between diagnosis and the start of treatment to just one day.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
› Verified 6 days ago
Entity Name | Denver Health And Hospital Authority |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1477569838 PECOS PAC ID: 4688583578 Enrollment ID: O20031105000211 |
News Archive
The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
The first mobile safety laboratory to operate under Biosafety Level 3 has been in use in South Africa since May 2011. As development of the Fraunhofer Institute for Biomedical Engineering in St. Ingbert, this special truck is used for testing and advising patients with AIDS and tuberculosis. The mobile laboratory can save patients' lives in remote areas because it cuts the waiting time between diagnosis and the start of treatment to just one day.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
› Verified 6 days ago
Entity Name | Healthone Clinic Services - Orthopedic Specialists Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1245556091 PECOS PAC ID: 5799972725 Enrollment ID: O20101203000060 |
News Archive
The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
The first mobile safety laboratory to operate under Biosafety Level 3 has been in use in South Africa since May 2011. As development of the Fraunhofer Institute for Biomedical Engineering in St. Ingbert, this special truck is used for testing and advising patients with AIDS and tuberculosis. The mobile laboratory can save patients' lives in remote areas because it cuts the waiting time between diagnosis and the start of treatment to just one day.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Wade R Smith, MD 4900 S Monaco St, #210, Denver, CO 80237-3486 Ph: (303) 209-2503 | Dr Wade R Smith, MD 701 E Hampden Ave, #515, Englewood, CO 80113-2736 Ph: (303) 209-2503 |
News Archive
The U.S. Environmental Protection Agency will continue validating its ToxCast screening tool by screening more than 100 drugs provided by Pfizer, GlaxoSmithKline, Sanofi-Aventis, and Merck. These drugs never entered the marketplace because they demonstrated different types and levels of toxicity when the pharmaceutical companies conducted the early stage clinical trials required by the Food and Drug Administration as part of the drug development process.
Results of the first-ever clinical drug trial for children with Progeria, a rare, fatal "rapid-aging" disease, demonstrate the efficacy of a farnesyltransferase inhibitor (FTI), a drug originally developed to treat cancer. The clinical trial results, completed only six years after scientists identified the cause of Progeria, included significant improvements in weight gain, bone structure and, most importantly, the cardiovascular system, according to The Progeria Research Foundation (PRF) and Boston Children's Hospital.
The first mobile safety laboratory to operate under Biosafety Level 3 has been in use in South Africa since May 2011. As development of the Fraunhofer Institute for Biomedical Engineering in St. Ingbert, this special truck is used for testing and advising patients with AIDS and tuberculosis. The mobile laboratory can save patients' lives in remote areas because it cuts the waiting time between diagnosis and the start of treatment to just one day.
Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.
› Verified 6 days ago
Dr. Judith Emily Kopinski, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 145 Inverness Dr E Ste 300, Englewood, CO 80112 Phone: 303-695-6060 Fax: 303-369-7776 | |
John S Woodward Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 799 E Hampden Ave, Suite 400, Englewood, CO 80113 Phone: 303-789-2663 Fax: 303-788-4871 | |
Dr. Christopher Rolf Johnson, MD Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 145 Inverness Dr E Ste 100, Englewood, CO 80112 Phone: 303-697-7463 | |
Philip Heyman, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 601 E Hampden Ave, Suite 500, Englewood, CO 80113 Phone: 303-744-7078 Fax: 303-744-0248 | |
Trevor Jordan Wait, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 175 Inverness Dr W, Englewood, CO 80112 Phone: 720-848-0000 | |
Dr. Steven J Morgan, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 701 E Hampden Ave, Suite 515, Englewood, CO 80113 Phone: 303-209-2503 Fax: 303-761-0803 | |
James T Muffly, M.D. Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 799 E Hampden Ave, Ste 310, Englewood, CO 80113 Phone: 303-788-7840 Fax: 303-788-7839 |